79 results about "Streptococcus lactis" patented technology

The invention provides an SNP (Single Nucleotide Polymorphism) site combination for identifying streptococcicosis resistance of tilapia and application of the SNP site combination. DNAs of tilapia tail fin tissues attacked by streptococcus agalactiae are re-sequenced, resistant and sensitive individuals of a tilapia population are screened, GWAS analysis is carried out, SNPs sites related to tilapia streptococcus agalactiae disease resistance are identified, functional gene annotation and enrichment analysis are carried out, two SNP sites LG1320881657 and LG1320548718 are screened, and the SNP sites related to tilapia streptococcus agalactiae disease resistance are obtained. The GG genotype of the LG1320881657 and the TT genotype of the LG1320548718 are the dominant genotypes related to the streptococcus agalactiae disease resistance of the tilapia mossambica. The tilapia mossambica resistant to streptococcosis is successfully screened by utilizing the two SNPs sites, effective SNPs are provided for developing tilapia mossambica anti-streptococcosis molecular marker-assisted breeding, excellent characters of parents are ensured, and the breeding efficiency is improved.

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

The invention discloses application of polypeptide compounds in prevention and treatment of pathogenic microorganisms. The compound has a synergistic effect on agricultural fungi such as rhizoctonia solani, Sclerotinia sclerotiorum, Botrytis cinerea, Fusarium graminearum, Pyricaria oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae, pyricularia oryzae and pyricularia oryzae. The method comprises the following steps: carrying out sterilization on plant bacteria such as Xanthomonas oryzae PXO99A, Xanthomonas axonophora dispsp.citrijx-6, Pseudomonas solanacearum (Smith) BNCC335855, Pseudomonas sp. The method is characterized by comprising the following steps of: killing Aspergillus flavus ACCC32601 (Aspergillus flavus), Penicillium expansum ACCC 30898 (Penicillium expansum. EXPANSum ACCC 30898), Monilinia coerulea ACCC 36263 (Aspergillus oryzae, Aspergillus niger, Aspergillus niger, Aspergillus niger, Aspergillus niger, Aspergillus niger, Aspergillus niger, Aspergillus niger and Aspergillus niger); the compound disclosed by the invention has a certain inhibition activity on various diseases caused by streptococcus agalactiae ATCC 27956, streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922 and Staphylococcus aureus, particularly, the compound Thiostreptin has a particularly remarkable inhibition effect on agricultural pathogenic bacteria, food-borne germs and cow mastitis germs, and is expected to be developed into a novel antibacterial drug, so that the compound disclosed by the invention can be used for preparing the antibacterial agent for preventing and treating various diseases caused by the streptococcus agalactiae ATCC 27956, the streptococcus dysgalactiae ATCC27957, the Escherichia coli ATCC 25922 and the Staphylococcus aureus.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention relates to the technical field of gene engineering, and particularly discloses streptococcus agalactiae WC1535 delta cps delta hylB as well as a construction method and application thereof. The streptococcus agalactiae WC1535 [delta] cps [delta] hylB is preserved in Guangdong Microbial Culture Collection Center on February 28, 2025, the preservation number is GDMCC NO.65955, and the address of the preservation unit is the 5th building, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. Compared with a traditional single-fragment deletion method, the toxicity of the deletion strain is not prone to being enhanced, and compared with a traditional injection immune vaccine, the gene deletion strain is used for preparing the tilapia oral live vaccine, the immune operation is simpler, and more labor cost is saved.

The invention discloses application of a series of quinine derivatives in preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of natural medicinal chemistry. According to the present invention, with the application of the derivative, the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 27956 and Streptococcus dysgalactiae ATCC 27957 can be provided, and the excellent inhibition activity can be provided on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 27956 and Streptococcus dysgalactiae ATCC 27957; the synthesis method of the compound is simple, and the compound has great application value in the aspect of natural product source compounds for preventing and treating cow mastitis. Structural formula of related compound as follows: # imgabs0 #

The invention relates to the technical field of biology, in particular to a detection method for tilapia streptococcus agalactiae resistance, a KASP primer group and application. According to the invention, the key SNP site of the ABCB4 gene, which is obviously associated with the streptococcus agalactiae disease resistance, of the tilapia is identified by a population genetics method, a typing method of the SNP site is developed by a KASP technology, efficient evaluation on disease resistance characters is realized, experimental data shows that the survival time of an AA genotype individual in a challenge test is prolonged compared with that of a GA / GG genotype individual, and the survival time of the AA genotype individual in the challenge test is obviously prolonged compared with that of a GA / GG genotype individual. The proportion of resistant fishes is remarkably increased, and genotype frequency distribution is strongly related to group disease resistance. According to the breeding strategy based on the SNP marker, the disease resistance of bred groups can be integrally improved, the morbidity and death rate are reduced, an efficient genetic improvement tool is provided for breeding of tilapia mossambica for resisting streptococcus agalactiae diseases, the loss of breeding diseases is reduced, and antibiotic dependence is reduced.

The invention relates to the technical field of biology, in particular to an SNP (Single Nucleotide Polymorphism) marker combination for identifying tilapia streptococcus agalactiae disease resistance and application thereof. The invention discloses 11 SNP loci significantly related to streptococcus agalactiae resistance in a tilapia UTRN gene, and constructs 18 SNP marker combinations for streptococcus agalactiae resistance phenotype identification, so that the resistance phenotype identification accuracy and hereditary stability can be effectively improved. Besides, according to the SNP typing primer and method based on the # imgabs0 # MALDI-TOF mass spectrum platform, high-throughput and high-precision genetic typing can be achieved, and the SNP typing primer and method have important application value in resistance phenotype identification and assistant selective breeding.

The invention discloses a zanthoxylum bungeanum leaf extract and a preparation method and application thereof.The preparation method includes the steps that zanthoxylum bungeanum leaves are cleaned, dried and then smashed, and zanthoxylum bungeanum leaf powder is obtained; condensing and extracting: taking the bunge pricklyash leaf powder, adding a solvent, heating, condensing and refluxing for a certain time, carrying out suction filtration after condensing and refluxing, collecting filtrate, repeatedly extracting for 2-5 times, adding the same volume of solvent each time, and combining the filtrate to obtain an extract; performing rotary evaporation: performing rotary evaporation on the extracting solution to obtain a concentrated solution; and drying: drying the concentrated solution, and grinding the dried concentrated solution into powder to obtain the bunge pricklyash leaf extract. The zanthoxylum bungeanum leaf extract prepared by the preparation method disclosed by the invention has an inhibiting effect on listeria monocytogenes, staphylococcus aureus, streptococcus agalactiae and bacillus cereus, provides a new way for preparing bacteriostatic products such as bacteriostatic drugs, bacteriostatic cleaning supplies and bacteriostatic feed additives, and is beneficial to development and utilization of zanthoxylum bungeanum leaf resources; the use value of bunge pricklyash leaves is improved, and resource waste is reduced.

The invention relates to the technical field of biology, in particular to a tilapia mossambica streptococcus agalactiae resistance related KASP molecular marker and application thereof. According to the invention, two SNP (Single Nucleotide Polymorphism) loci, namely SNP-1 and SNP-2, which are remarkably associated with resistance are screened based on an intron region of an EGFRX2 gene of tilapia mossambica, a typing method of the loci is developed through a KASP technology, and relevance between the genotype of the SNP-1 and a resistance phenotype is verified. Furthermore, streptococcus agalactiae resistance dominant diplotype individuals are screened in combination with double SNP loci, and the survival rate of a challenge experiment is remarkably improved. The detection kit provided by the invention can realize high-throughput and high-precision typing, is suitable for tilapia mossambica resistance genotype identification and molecular marker-assisted breeding, provides an efficient genetic improvement tool for tilapia mossambica disease-resistant breeding, and is beneficial to reduction of breeding disease loss and reduction of antibiotic dependence.

Compositions comprising 5. salivarius strain SALI-10 and / or salivarius 10 peptide are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.

The invention discloses cryptolepine alkaloid derivatives, which comprise application of cryptolepine derivatives BYT-01 to BYT-09, neocryptolepine derivatives XBYT-01 to XBYT-45, iso-cryptolepine derivatives YBYT-01 to YBYT-21 and iso-cryptolepine derivatives YXBYT-01 to YXBYT-04 in the aspect of preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of natural medicinal chemistry. The cryptolepine alkaloid derivative has the advantages that the cryptolepine alkaloid derivative has good inhibitory activity on dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922 and Staphylococcus aureus, and the cryptolepine alkaloid derivative has great development value in the aspect of replacing antibiotics to become a source compound of a natural product for preventing and treating dairy cow mastitis.

The invention discloses application of a licoflavone compound in resisting food-borne pathogenic bacteria and dairy cow mastitis pathogenic bacteria. The licoflavone compound has the advantages that the licoflavone compound can be used for treating food-borne bacterial diseases caused by food-borne bacteria such as escherichia coli, bacillus cereus, listeria monocytogenes and salmonella enteritidis; food-borne fungal diseases caused by food-borne fungi such as aspergillus flavus, penicillium expansum and monilinia coerulea; the licochalcone A shows certain inhibitory activity on dairy cow mastitis pathogenic bacteria caused by streptococcus agalactiae, streptococcus dysgalactiae, escherichia coli and staphylococcus aureus, and particularly has an obvious inhibitory effect on food-borne pathogenic bacteria and dairy cow mastitis pathogenic bacteria by three licochalcone A with different contents. The compound disclosed by the invention is simple in structure and relatively high in safety, and is expected to be developed into a novel antibacterial drug.

The invention discloses a multiple qPCR (quantitative polymerase chain reaction) detection reagent for detecting neonatal gastrointestinal infection pathogens. The kit comprises specific primers and probes for detecting enterohemorrhagic escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, streptococcus agalactiae, klebsiella pneumoniae, staphylococcus epidermidis, beta hemolytic streptococcus, salmonella, rotavirus and adenovirus. According to the invention, different fluorescently-labeled probes are utilized to add specific primers and probes of multiple pathogens into a reaction system to detect multiple targets at the same time, and the method has the advantages of good specificity, high sensitivity, short detection period, capability of simultaneously detecting multiple pathogens, rapidness, simplicity, convenience and economy; a convenient method is provided for rapid detection of pathogens causing neonatal gastrointestinal infection, and the kit has important significance in epidemiological research, clinical early molecular diagnosis and the like.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The present invention relates to an immunogenic polysaccharide-protein conjugate comprising a capsular polysaccharide (CP) from Streptococcus agalactiae (commonly known as group B streptococcus (GBS)) and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the sialic acid level of the CP is higher than about 60%. The present invention also relates to methods of making the conjugate and immunogenic compositions comprising the conjugate. The present invention also relates to an immunogenic composition comprising a polysaccharide-protein conjugate, wherein the conjugate comprises CP from GBS serotype IV and at least one additional serotype. The present invention further relates to methods of using the compositions disclosed herein to induce an immune response against GBS in a subject and / or to reduce or prevent invasive GBS disease in a subject. The antibodies generated can be used for the treatment or prevention of GBS infection by passive immunotherapy.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention discloses application of a series of isosteviol derivatives in preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of medicinal chemistry. According to the present invention, with the application of the derivative of the present invention, the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957 can be provided, and the application of the derivative of the present invention provides the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957, the synthesis method of the compound is simple, the raw materials are cheap and easy to obtain, and the compound has great development value in the aspect of natural product source compounds for preventing and treating cow mastitis. The structural formula of the compound is shown in the specification.

The invention discloses a streptococcus agalactiae attenuated strain, a vaccine and application of the streptococcus agalactiae attenuated strain, and belongs to the technical field of veterinary biological products. The streptococcus agalactiae attenuated strain is obtained by knocking out a marR gene of a streptococcus agalactiae virulent strain HN016; wherein the nucleotide sequence of the marR gene is as shown in SEQ ID NO: 1. After the marR gene of the streptococcus agalactiae virulent strain HN016 is knocked out, the streptococcus agalactiae attenuated strain of which the virulence is remarkably reduced is obtained, and after the streptococcus agalactiae attenuated strain is prepared into the vaccine, the survival rate of aquatic animals infected with streptococcus agalactiae can be remarkably improved, so that the survival rate of the aquatic animals infected with streptococcus agalactiae is improved. The streptococcus agalactiae attenuated strain has a good application prospect in preparation of drugs for preventing and / or treating streptococcus agalactiae infection of aquatic animals.

The present application relates to a Pediococcus acidilactici capable of reducing the activation of hippocampal microglia cells and its application, belonging to the technical field of microorganisms. The Pediococcus acidilactici described in the present application is Pediococcus acidilactici CCFM1344, which was preserved in the Guangdong Microbial Culture Collection Center on September 12, 2023, with the preservation number GDMCC NO.63800. The preservation address is Building 59, 5th Floor, Guangdong Microbial Institute, 100 Middle Martyrs Road, Guangzhou. The Pediococcus acidilactici described in the present application can inhibit the over-activation of microglia cells caused by chronic stress, reduce the concentration of pro-inflammatory factors in the hippocampus of the brain, thereby relieving the activation of microglia cells in the hippocampus of the brain caused by chronic stress, and has excellent application prospects.

The invention relates to the field of microorganisms, in particular to a streptococcus lactis strain SKLAN202403XW for degrading solanine and application of the streptococcus lactis strain SKLAN202403XW. The preservation number of the strain is CGMCC No.30021. The strain and a preparation thereof can effectively reduce the content of solanine in potato stems and leaves, significantly reduce the toxicity of the potato stems and leaves, and provide a basis for subsequent development and utilization.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The present invention relates to a multiplex gene detection system for viral and bacterial infection of the central nervous system, comprising forward and reverse primers for detecting enterovirus, human double echovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Streptococcus pneumoniae, varicella zoster virus, mumps virus, cytomegalovirus, herpes simplex virus type 1, herpes simplex virus type 2, Neisseria meningitidis, Epstein-Barr virus, Streptococcus agalactiae, Haemophilus influenzae, human herpes virus type 6, Escherichia coli K1 and Japanese encephalitis virus, and the detection sample is cerebrospinal fluid. The multiplex gene detection product for viral and bacterial infection of the central nervous system of the present invention has high throughput, low cost, high sensitivity and good specificity, and is used for synchronous identification and semi-quantitative analysis of multiple viral and bacterial infections of the central nervous system.

The present application relates to the field of biotechnology, and more particularly to a detection method for resistance of tilapia to streptococcosis, a KASP primer set and application. The present application identifies a key SNP site of the ABCB4 gene significantly associated with resistance of tilapia to streptococcosis by the method of population genetics, and develops a genotyping method for the SNP site by KASP technology, thereby realizing efficient evaluation of the disease-resistant trait. Experimental data show that the survival time of AA genotype individuals in the challenge test is longer than that of GA / GG genotype individuals, the proportion of resistant fish is significantly improved, and the genotype frequency distribution is strongly correlated with the disease resistance of the population. The breeding strategy based on the SNP marker can improve the overall disease resistance of the breeding population and reduce the mortality rate, thereby providing an efficient genetic improvement tool for breeding of tilapia resistant to streptococcosis, and helping to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The present application relates to the technical field of microorganism, and particularly relates to a streptococcus lactis with a cat dandruff treatment function and application thereof. Pediococcus acidilactici The streptococcus lactis is preserved in the Guangdong Provincial Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67035. The streptococcus lactis and the inactivated bacteria solution provided in the present application have good inhibitory effects on trichophyton mentagrophytes and mycosporum gypseum. The streptococcus lactis provided in the present application can also be used for treating cat dandruff, and compared with ketoconazole cream, the streptococcus lactis has faster effect and shorter treatment cycle.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

The application belongs to the technical field of biological medicine, and particularly relates to application of pantothenic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for enhancing sensitivity of pathogenic bacteria to daptomycin. It is found for the first time that addition of pantothenic acid or a pharmaceutically acceptable salt thereof can improve the sensitivity of gram-positive bacteria including Staphylococcus aureus, Streptococcus agalactiae and Corynebacterium diphtheriae to daptomycin, significantly improve the bactericidal effect, and further research shows that pantothenic acid or a pharmaceutically acceptable salt thereof can promote the clearance, formation and reduction of pathogenic bacteria biofilm by daptomycin. The finding opens up a new way for overcoming antibiotic resistance and optimizing anti-infection treatment strategies.

The invention discloses a novel application of Xenocoumacin 1 in prevention and treatment of pathogenic bacteria of cow mastitis, and belongs to the field of natural pharmaceutical chemistry. According to the present invention, with the application of the Xenocoumacin 1, the broad-spectrum and efficient inhibition activity can be provided for the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922, and Staphylococcus aureus (Staphylococcus aureus), and the broad-spectrum and efficient inhibition activity can be provided for the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922, and Staphylococcus aureus (Staphylococcus aureus); therefore, the Xenocoumacin 1 has development potential in the aspect of being developed into the natural source medicine for preventing and treating the cow mastitis.

The invention provides a fermentation method for improving titer of nisin, which comprises the following steps of: performing seed culture on a nisin seed solution, transferring the nisin seed solution into a fermentation culture medium, performing fermentation culture, and achieving a manner of improving the titer through a fermentation method of feeding, supplementing materials and introducing air. In the fermentation process, a 5% (g / L) phytic acid solution is added in a fed-batch mode when the period is 10-16 h till fermentation is finished. Before the fermentation period is 14 hours, air is not introduced for culture, the tank pressure is 0 Mpa, 0.01-0.05 vvm of air is introduced from 14 hours, and the tank pressure is 0.03 Mpa until the fermentation is finished. The phytic acid solution is supplemented in the middle and later periods of fermentation, the metabolism speed can be controlled, thallus oxidation death and autolysis are prevented, and the biological value is indirectly improved. A trace amount of air is introduced, so that the generation of lactic acid can be inhibited, tricarboxylic acid circulation is properly enhanced, and the synthesis efficiency of precursor amino acid is improved. Under the combined action of the two, the effects of controlling and prolonging the primary metabolism time, reducing the yield of lactic acid and obviously improving the titer increase in the later period are achieved.